Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia

Thrombocytopenia is common in patients with myelofibrosis (MF) and is a well-established adverse prognostic factor. Both of the approved Janus kinase (JAK) inhibitors, ruxolitinib and fedratinib, can worsen thrombocytopenia and have not been evaluated in patients with severe thrombocytopenia (platel...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Mesa, Ruben, Talpaz, Moshe, Kiladjian, Jean-Jacques, Harrison, Claire N., Oh, Stephen T., Vannucchi, Alessandro M., Rampal, Raajit, Scott, Bart L., Buckley, Sarah A., Craig, Adam R., Roman-Torres, Karisse, Mascarenhas, John O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Myeloproliferative Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244834/
https://www.ncbi.nlm.nih.gov/pubmed/34551507
http://dx.doi.org/10.3324/haematol.2021.279415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244834/
https://www.ncbi.nlm.nih.gov/pubmed/34551507
http://dx.doi.org/10.3324/haematol.2021.279415

Ejemplares similares